CA2386381A1 - Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence - Google Patents
Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence Download PDFInfo
- Publication number
- CA2386381A1 CA2386381A1 CA002386381A CA2386381A CA2386381A1 CA 2386381 A1 CA2386381 A1 CA 2386381A1 CA 002386381 A CA002386381 A CA 002386381A CA 2386381 A CA2386381 A CA 2386381A CA 2386381 A1 CA2386381 A1 CA 2386381A1
- Authority
- CA
- Canada
- Prior art keywords
- tramadol
- desmethyl
- mono
- urinary incontinence
- urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 34
- 229960004380 tramadol Drugs 0.000 title claims abstract description 25
- 206010046543 Urinary incontinence Diseases 0.000 title claims abstract description 21
- UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 title claims abstract description 7
- UWJUQVWARXYRCG-UHFFFAOYSA-N o-desmethyltramadol Chemical compound CN(C)CC1CCCCC1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 206010027566 Micturition urgency Diseases 0.000 claims description 18
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 239000002585 base Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 13
- 230000027939 micturition Effects 0.000 description 11
- 230000002485 urinary effect Effects 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- FRVHJVATKMIOPQ-PAPWGAKMSA-N 17-Methyl-5-alpha-androst-2-en-17-beta-ol Chemical compound C([C@@H]1CC2)C=CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 FRVHJVATKMIOPQ-PAPWGAKMSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- -1 granuloo Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 241001535291 Analges Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100042676 Mus musculus Skap2 gene Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- UWJUQVWARXYRCG-DZGCQCFKSA-N 3-[(1s,2s)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol Chemical compound CN(C)C[C@@H]1CCCC[C@@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-DZGCQCFKSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101100311260 Caenorhabditis elegans sti-1 gene Proteins 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 101150036577 fl11 gene Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000263 levallorphan Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947747.7 | 1999-10-05 | ||
| DE19947747A DE19947747A1 (de) | 1999-10-05 | 1999-10-05 | Verwendung von (+)-Tramadol, O-Demethyltramadol bzw. (+)-O-Demethyltramadol zur Therapie der Harninkontinenz |
| DE20002943.6 | 2000-02-21 | ||
| DE20002943U DE20002943U1 (de) | 2000-02-21 | 2000-02-21 | Arzneimittel enthaltend O-desmethyl-N-mono-desmethyl-tramadol |
| PCT/EP2000/009420 WO2001024783A2 (de) | 1999-10-05 | 2000-09-27 | Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2386381A1 true CA2386381A1 (en) | 2001-04-12 |
Family
ID=26055167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002386381A Abandoned CA2386381A1 (en) | 1999-10-05 | 2000-09-27 | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6660774B2 (https=) |
| EP (1) | EP1217998B1 (https=) |
| JP (1) | JP5477881B2 (https=) |
| AT (1) | ATE368455T1 (https=) |
| AU (1) | AU7907600A (https=) |
| CA (1) | CA2386381A1 (https=) |
| DE (1) | DE50014532D1 (https=) |
| ES (1) | ES2291223T3 (https=) |
| HK (1) | HK1047707A1 (https=) |
| HU (1) | HUP0202776A2 (https=) |
| MX (1) | MXPA02003491A (https=) |
| PE (1) | PE20010623A1 (https=) |
| WO (1) | WO2001024783A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946290B2 (en) | 2001-09-18 | 2015-02-03 | Gruenenthal Gmbh | Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10049483A1 (de) * | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte 1-Aminobutan-3-ol-Derivate |
| FR2815691B1 (fr) * | 2000-10-20 | 2003-08-15 | Valois Sa | Bille de clapet |
| DE10059413A1 (de) * | 2000-11-30 | 2002-06-20 | Gruenenthal Gmbh | Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz |
| DE10224107A1 (de) * | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| DE10224624A1 (de) * | 2002-05-30 | 2003-12-11 | Gruenenthal Gmbh | Metabolite und Prodrugs von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol |
| DE10224556A1 (de) * | 2002-05-31 | 2004-01-08 | Grünenthal GmbH | 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen |
| DE10233048A1 (de) * | 2002-07-19 | 2004-01-29 | Grünenthal GmbH | Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken |
| US20050182131A1 (en) * | 2002-07-19 | 2005-08-18 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| JP4059259B2 (ja) | 2005-06-30 | 2008-03-12 | ヤマハ株式会社 | スピーカシステムおよびスピーカエンクロージャー |
| WO2007018234A1 (ja) * | 2005-08-10 | 2007-02-15 | Nippon Shinyaku Co., Ltd. | 尿道内圧上昇作用剤 |
| DK1940467T3 (da) | 2005-09-09 | 2017-02-13 | Paladin Labs Inc | Lægemiddelsammensætning med langvarig frigivelse |
| CN101252932B (zh) | 2005-09-09 | 2012-10-03 | 安吉利尼莱博法姆有限责任公司 | 用于一天给药一次的曲唑酮组合物 |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| EP2281558A1 (en) * | 2009-08-06 | 2011-02-09 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors |
| US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
| US11000488B2 (en) | 2019-03-22 | 2021-05-11 | Syntrix Biosystems Inc. | Treating pain using desmetramadol |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2095523C (en) | 1991-09-06 | 2004-06-22 | Robert B. Raffa | Composition comprising a tramadol material and acetaminophen and its use |
| AU657351B2 (en) | 1991-09-06 | 1995-03-09 | Mcneilab, Inc. | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use |
| GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| DE19601744C2 (de) | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
| EP0969818B1 (en) * | 1997-03-11 | 2004-09-08 | Arakis Ltd. | Dosage forms comprising separate portions of r- and s-enantiomers |
| DE19712398A1 (de) * | 1997-03-25 | 1998-10-01 | Gruenenthal Gmbh | Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel |
| EP1005861B1 (en) | 1997-04-11 | 2005-06-29 | Nippon Shinyaku Co., Ltd. | Remedies for frequent urination and urinary incontinence |
| GB9709972D0 (en) * | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
-
2000
- 2000-09-25 PE PE2000001005A patent/PE20010623A1/es not_active Application Discontinuation
- 2000-09-27 MX MXPA02003491A patent/MXPA02003491A/es unknown
- 2000-09-27 HU HU0202776A patent/HUP0202776A2/hu unknown
- 2000-09-27 EP EP00969311A patent/EP1217998B1/de not_active Expired - Lifetime
- 2000-09-27 HK HK02109384.3A patent/HK1047707A1/zh unknown
- 2000-09-27 ES ES00969311T patent/ES2291223T3/es not_active Expired - Lifetime
- 2000-09-27 WO PCT/EP2000/009420 patent/WO2001024783A2/de not_active Ceased
- 2000-09-27 AU AU79076/00A patent/AU7907600A/en not_active Abandoned
- 2000-09-27 JP JP2001527782A patent/JP5477881B2/ja not_active Expired - Fee Related
- 2000-09-27 AT AT00969311T patent/ATE368455T1/de active
- 2000-09-27 DE DE50014532T patent/DE50014532D1/de not_active Expired - Lifetime
- 2000-09-27 CA CA002386381A patent/CA2386381A1/en not_active Abandoned
-
2002
- 2002-04-05 US US10/116,123 patent/US6660774B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946290B2 (en) | 2001-09-18 | 2015-02-03 | Gruenenthal Gmbh | Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02003491A (es) | 2002-08-20 |
| PE20010623A1 (es) | 2001-07-07 |
| EP1217998B1 (de) | 2007-08-01 |
| ATE368455T1 (de) | 2007-08-15 |
| ES2291223T3 (es) | 2008-03-01 |
| WO2001024783A2 (de) | 2001-04-12 |
| JP5477881B2 (ja) | 2014-04-23 |
| US20030069314A1 (en) | 2003-04-10 |
| AU7907600A (en) | 2001-05-10 |
| HK1047707A1 (zh) | 2003-03-07 |
| WO2001024783A3 (de) | 2002-02-28 |
| EP1217998A2 (de) | 2002-07-03 |
| HUP0202776A2 (hu) | 2003-02-28 |
| US6660774B2 (en) | 2003-12-09 |
| DE50014532D1 (de) | 2007-09-13 |
| JP2003510350A (ja) | 2003-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2386381A1 (en) | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence | |
| CA2205134C (en) | A method for treating vascular headaches | |
| JP4085433B2 (ja) | 頻尿・尿失禁治療剤 | |
| JP2002544160A (ja) | トラマドールの鎮痛効力を増強するためおよびその有害副作用を減弱するための組成物を含むオピオイド拮抗薬 | |
| BRPI0213653B1 (pt) | Formulação farmacêutica que contém o 3-(3- dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo | |
| Jenner et al. | Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset | |
| EP3463312A1 (en) | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder | |
| KR20170086659A (ko) | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 | |
| NO333016B1 (no) | Anvendelse av en kombinasjon av utvalgte opioider med muskarinantagonister og legemiddel inneholdende kombinasjonen | |
| Mizutani et al. | TAS-303, a novel selective norepinephrine reuptake inhibitor that increases urethral pressure in rats, indicating its potential as a therapeutic agent for stress urinary incontinence | |
| van Der Pluijm et al. | SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease | |
| CA2430332C (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence | |
| US20090291939A1 (en) | Treating Alcohol And Or Substance Abuse By Antagonizing Alpha 2 Adrenergic Receptors With Weak Dopamine Blocking | |
| EP1740174A1 (en) | Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of enuresis | |
| EP4340837A1 (en) | Methods of treating interstitial cystitis/bladder pain syndrome | |
| SK287536B6 (sk) | Použitie substituovaných zlúčenín 6-dimetylaminometyl-1-fenyl- cyklohexanónu na terapiu inkontinencie moču | |
| SK287701B6 (sk) | Použitie zlúčenín 6-dimetylaminometyl-1-fenyl-cyklohexánu na výrobu liečiva | |
| US20040248932A1 (en) | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines in the treatment of chronic and neuropathic pain, migraine headaches, and urge, stress and mixed urinary incontinence | |
| EP1652532A1 (en) | Medicinal composition | |
| US20040248933A1 (en) | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | |
| WO2016115223A1 (en) | Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments | |
| Amobi et al. | Effects of thioridazine on mechanical responses of human vas deferens induced by noradrenaline or potassium | |
| FR2895259A1 (fr) | Methodes de traitement des incontinences urinaires | |
| WO2019131902A1 (ja) | 腹圧性尿失禁および便失禁の治療薬 | |
| RU2769555C2 (ru) | Фармацевтическая композиция для лечения острой и хронической боли, содержащая полмакоксиб и трамадол |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |